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Article
Healing properties of surface-coated
polycaprolactone-co-lactide scaffolds:
A pilot study in sheep
Claudia Rentsch1,2, Wolfgang Schneiders1,2, Ricarda Hess3, Barbe Rentsch4,
Ricardo Bernhardt3, Kathrin Spekl5, Konrad Schneider6, Dieter Scharnweber3,7,
Achim Biewener1,2 and Stefan Rammelt1,2,7
Abstract
The aim of this pilot study was to evaluate the bioactive, surface-coated polycaprolactone-co-lactide scaffolds as bone
implants in a tibia critical size defect model. Polycaprolactone-co-lactide scaffolds were coated with collagen type I and
chondroitin sulfate and 30 piled up polycaprolactone-co-lactide scaffolds were implanted into a 3 cm sheep tibia critical
size defect for 3 or 12 months (n¼ 5 each). Bone healing was estimated by quantification of bone volume in the defects
on computer tomography and microcomputer tomography scans, plain radiographs, biomechanical testing as well as by
histological evaluations. New bone formation occurred at the proximal and distal ends of the tibia in both groups. The
current pilot study revealed a mean new bone formation of 63% and 172% after 3 and 12 months, respectively. The
bioactive, surface coated, highly porous three-dimensional polycaprolactone-co-lactide scaffold stack itself acted as a
guide rail for new bone formation along and into the implant. These preliminary data are encouraging for future
experiments with a larger group of animals.
Keywords
Polycaprolactone-co-lactide scaffold, collagen type I and chondroitin sulfate, sheep, tibia defect, bone healing
Introduction
Current clinical options in the treatment of critical size
bone defects due to trauma, inflammation, and tumor
resection are limited, and pose a continuous challenge
in orthopedic surgery. Although autogenic and allo-
genic bone grafting are established clinical methods,
none of these techniques is optimal in terms of hospi-
talization time, stability, storage, immune reaction,
infection risk, pain, and availability.1,2
Actual investigations of new bone implants using
different biomaterials, such as hydroxyaptite, polymers,
metals, and composites,3–5 partly in combination with
growth factors,6 platelet-rich plasma, bone marrow,
mesenchymal stem cells,7–9 or gene therapy,10,11 have
been proposed as alternatives, but until now only a
few of the unconventional bone graft techniques have
been incorporated into the clinical setting.12–14
Biocompatible and resorbable polymers like poly("-
caprolactone) and poly(lactic acid) and their copoly-
mers, are promising materials for biomedical
applications in bone and cartilage repair15,16 drug deliv-
ery systems17 and as surgical sutures.18
In addition to the graft itself, the extracellular matrix
(ECM) plays an important role for bone forming and
bone resorbing cells in controlling development, main-
taining homeostasis, and guiding regeneration. Type I
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collagen (coll I), the key organic structure of the ECM,
can be immobilized to the surface of implants, main-
taining its structural properties and creating an artifi-
cial ECM. The positive effects of coll I on bone
remodeling19,20 can be further enhanced by adding gly-
cosaminoglycans like chondroitin sulfate (cs). CS is
used in matrices in combination with coll I as a struc-
tural component in tissue regeneration.21–25
The aim of this pilot study was to investigate the
healing properties of coll I/cs coated polycaprolac-
tone-co-lactide (PCL, trade name; Catgut GmbH,
Markneukirchen) scaffolds using a large animal
model. The three-dimensional scaffold stack (composed
of 30 single scaffolds) was implanted in a 3 cm tibiae
critical size defect in sheep. New bone formation was
determined over a period of 3 and 12 months by histo-
logical, radiological, computer tomographical (CT),
and biomechanical investigations.
Material and methods
Production and coating of PCL scaffolds
The copolymer of L-lactide and "-caprolactone (75/25)
was melt spun and resulted in a synthetic, resorbable,
monofilament fiber, available as PCL suture (Catgut
GmbH, Germany). A traditional manufacturing tech-
nique (embroidery) was used to produce the scaffolds
presenting a triaxial structure (deposition of the thread
in a triangular assembly; 0/60/120 netting) with a stitch
length of 1.4mm and a mesh spacing of 1.2mm. The
resulting round, textile scaffolds with 19mm outer
and 10mm inner diameter had a height of ca 1mm
(Figure 1(a)). These scaffolds can be piled up,
depending on the defects size, to create a real three-
dimensional implant (Figure 1(c)).
The coll I/CS matrix coating was produced as pre-
viously described.22 Porcine skin coll I (MBP GmbH,
Neustadt-Glewe, Germany) was suspended in 0.01M
acetic acid, diluted in phosphate buffer (60mM Pi,
270mM NaOH, pH 7.4) with 1.25mg/mL CS A and
B (Sigma–Aldrich, St. Louis, MO) to 2.5mg/mL. After
scaffold coating, a cross-linking step followed by
adding 0.1M N-(3-dimethylaminopropyl)-N0-ethylcar-
bodiimide hydrochloride and 0.05M N-hydroxysucci-
nimide (Sigma–Aldrich, St. Louis, MO) in 0.1M
phosphate buffer at pH 5.5/40% ethanol.
Microcomputer tomography of the scaffold
The general porosity and the pore-size distribution of
the three-dimensional scaffold stack were determined
using non-destructive microcomputer tomography
(mCT) analysis with the Scanco vivaCT 75 system
(Scanco Medical, Brüttisellen, Switzerland). The sam-
ples were measured with radiological energy of 55 keV
and 1500 projections. The voxel resolution of the recon-
structed volume was 20 mm. The porosity and the pore
size distribution were measured with the Scanco evalu-
ation software.
Surgical procedure
This study has been licensed by the regional veterinary
board (24D-9168.11-1-2006-17). All animals were cared
for according to the European guidelines for the care
and use of laboratory animals (Directive 24.11.1986,
86/609/CEE).
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Figure 1. PCL scaffold: (a) embroidered, single PCL scaffold, the 10mm inner space was prepared to allow the piling around the
marrow nail, (b) pore size distribution of the implant, and (c) presentation of the three-dimensional scaffold stack composed of 30
single PCL scaffolds.
PCL: polycaprolactone-co-lactide.
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A total number of 10 female sheep with an average
body weight of 65 kg was used for this study. Animals
achieved an intramuscular (IM) premedication of xyla-
zine (Rompun, Bayer, Germany, 0.9mg/kg body
weight) as well as a prophylactic amoxicillin antibiotic
therapy (Duphamox, Pfizer AG, Zürich, Switzerland,
15mg/kg body weight) prior to surgery. Surgery was
carried out in a lateral decubitus position under general
anesthesia (induced with sodium thiopental and main-
tained via inhalation of a mixture of nitrous oxide and
2% isoflurane).
A 3 cm long mid-diaphyseal segment was removed
from the left tibia of each sheep. The defect was stabi-
lized by a 20 cm long prototype tibial nail (UTN,
Clinical House GmbH, Bochum, Germany). For the
insertion of the nail, a longitudinal incision was made
over the knee and the patellar tendon was split in the
middle. An inlet hole was created at the level of the
tibial tuberosity. The nail was inserted without previous
reaming of the medullary canal through the tibia head,
while the diaphysis was osteotomized with an air-oscil-
lating saw through an anteromedial incision 6 cm below
the knee joint (Figure 2(a) and (b)). The 3 cm bone
segment was removed with the periosteum and replaced
with a Rebofacin Bone Cement R spacer (Biomet
GmbH, Ried, Switzerland), molded by hand to the
shape of the resected bone part (Figure 2(c)). The sur-
gical field was constantly washed with sterile phos-
phate buffer saline (PBS) while the bone cement
polymerized. All nails were locked proximally and dis-
tally with two locking screws of 40mm length and 4mm
diameter (Synthes GmbH, Umkirch, Germany).
To reduce weight bearing on the operated leg, the
achilles tendon was cut percutaneously. Subcutaneous
tissue and skin were closed using MARILIN and
MARIDERM suture material (Catgut GmbH,
Figure 2. Surgical procedure: (a) insertion of the 20 cm long prototype tibia nail, (b) osteotomy of the tibia mid-diaphysis using an air-
oscillating saw, (c) Rebofacin Bone Cement R spacer filled the 3 cm defect size for 6 weeks, (d) removed bone cement, proximal and
distal tibia end visible as well the marrow nail, (e) 30 inserted coll I/CS scaffolds and (f) final X-ray control (PCL scaffolds are not
detectable at radiographs).
coll I/cs: Type I collagen/chondroitin sulfate; PCL: polycaprolactone-co-lactide.
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Markneukirchen, Germany) under routine procedures.
Six weeks later, a 6 cm incision was made at the diaph-
ysis orientated at the previous scar and the bone cement
was carefully removed (Figure 2(d)). Finally, the defect
was filled with 30 coll I/CS scaffolds for 3 or 12 months
(Figure 2(e)). For that, the single scaffold discs were cut
open on one side, thread around the marrow nail and
piled up until the defect was completely filled.
Pain control was managed by 75mg carprofen
(Rimadyl, Pfizer AG, Zürich, Switzerland) IM, and
antibiotic prophylaxis was carried out through three
subsequent doses of 150mg Duphamox IM. Animals
were euthanized after 3 or 12 months with a lethal
dose of T-61 (Hoechst Roussel Vet, Wiesbaden,
Germany). Screws and nail were removed directly
after tibia preparation.
Radiography
Radiographs were taken with a mobile X-ray unit
(AMX 4, GE Healthcare, Buckinghamshire, UK)
using 52 kV and 2.5 mAs.
Computer tomography
Explanted tibiae of the 3-month group were assessed
for apparent bone mineral density with a CT scanner
(SOMATOM Sensation 16, Siemens Medical Solutions
USA, Inc., Malvern, PA). The scan was done using a
high-resolution bone window level setting tomography
with 120 kV, 166mA. The images were reconstructed
with 0.6mm thick slices using SIENET MagicView
300 analyzing software (Siemens, Erlangen,
Germany). CT scans were quantified for new bone for-
mation in the defect zone. The defect area was visually
localized between lateral and distal intact cortical bone.
mCT Analysis of the tibia (12-month group)
Explanted tibiae of the 12-month group were assessed
with a non-destructive mCT analysis using the Scanco
vivaCT 75 systems (Scanco Medical, Brüttisellen,
Switzerland). The samples were measured with radio-
logical energy of 70 keV and 500 projections. The voxel
resolution of the reconstructed images was 70 mm. The
new bone volume within the defect area was measured
with the Scanco evaluation software.
Histology
Explants were fixed in 4% buffered formalin for at
least 7 days.
Three-month group: The defect area was localized by
measuring the distance between proximal and dis-
tal locking screw and the visible callus formation.
The defect zone was cut in seven equal section planes
of 0.5 cm, beginning and ending beyond the implant
area. Each section plane was separated into quarters
to fit the embedding cube. The samples were washed,
decalcified for 4 weeks in ethylenediaminetetraacetic
acid (to adjust pH to 7.4–7.6 use NaOH), dehydrated
overnight in a Shandon Hyper Center tissue processor
(Rankin Biomedical Corp., Clarkston, MI), and
embedded in methylmetacrylate (Technovit 9100 New,
Heraeus Kulzer GmbH, Werheim, Germany) according
to manufacturer instructions. Sections of 3 mm were cut
(rotation microtome RM2055, Leica Microsystems,
Wetzlar, Germany), methylmethacrylate was removed
using xylene for 2 20min, 2-methoxyethylacetat for
2 20min, acetone for 2 5min, and 80% ethanol,
and stained for light microscopy (Leica DMRBE
Research Microscope, Camera Leica DC300, Leica
Microsystems, Wetzlar, Germany). Presented images
were taken from the central part of the 3 cm defect area.
Twelve-month group: The samples of the 12-month
group (after biomechanical testing) were
dehydrated overnight and embedded in methylmetacry-
late according to manufacturer instructions. Special
glass slides (5 10 cm2, Langenbrinck Labor- und
Medizintechnik, Emmendingen, Germany) were used
to allow the application of the longitudinal-sectioned
defect zone. Sections of 10mm were obtained with the
Exakt cutting and grinding equipment (Exakt,
Norderstedt, Germany) and stained for light
microscopy.
Masson–Goldner trichrome staining. Samples were stained
with Ponceau acid fuchsin for 5min, wash in acetic
acid, 1% and place in acid-Orange G solution. Rinse
in acetic acid, 1% for 30 s and stain in light green for
5min. Rinse in acetic acid, 1%, for 5min and counter
stain by hematoxylin staining according to Weigert
(15min).
Modified Masson–Goldner trichrome staining. Trichrome
staining according to Masson–Goldner combines
Ponceau (5min), Orange G (5min), and anilin blue tar-
trazine solution (15min). Tartrazine stains collagen
structures in yellow and in combination with anilin
blue which also stains collagen, the final coloring results
are various shades of green to yellow.
Sections were always washed with 3% acetic acid
between every staining step. Nuclei (brown) were coun-
ter stained by hematoxylin staining according to
Weigert (15min).
1A4-Actin staining. For immunohistology, 3 mm sections
were incubated with the primary antibody (mouse anti-
human smooth muscle Actin, clone 1A4, DAKO,
Glostrup, Denmark) overnight at 4C, than incubated
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with biotin conjugated bridging antibody 1:150 in block-
ing solution (1% BSA in PBS, 30min, 37C) and finally
incubated in avidin-biotin conjugated peroxidase
(Vectastain universal Elite Kit, Vector Laboratories,
Burlingame, CA) for 30min. The immune reaction was
visualized with Romulin (Biocare Medical, Concord,
CA) for 15min at room temperature. Sections were
counterstained with hematoxylin (Merck, Darmstadt,
Germany; 5min). Samples incubated without primary
antibody were used as control.
Biomechanical testing
The explanted tibiae of the 12-month group were fixed
to a biomechanical universal testing machine (TIRA
test 2300, Schalkau, Germany). A three-point bending
test was conducted using 2N pre-load and a test load-
ing speed of 10mm/min until the fracture occurred. The
contralateral tibiae were used as a reference. The max-
imum load until failure and the stiffness (dividing the
load at failure by the displacement at failure) were cal-
culated and compared to the control group.
Results
mCT of the PCL scaffold stack
Figure 1(c) shows a three-dimensional reconstruction of
the mCT analysis of the PCL scaffold stack, which rep-
resents the implant for the 3 cm critical size defect in the
sheep tibiae. The stack showed a homogeneously dis-
tributed interconnected porosity of 87% and a main
pore size range of 0.1–0.8mm distributed over the
whole stack (Figure 1(b)).
Complications
Two animals of the 12-month group sustained a tibial
shaft fracture after nail insertion and had to be fixed
with a cerclage wire.
During the entire course of the experiment, two
hardware failures occurred (each in one group). The
animals showed a broken intramedullary nail at the 6-
week radiographic control and were excluded from fur-
ther analysis.
Radiography, CT and histology at 3 months
There was no callus formation detectable after 6 weeks
of bone cement implantation (X-ray not shown). Six
weeks after scaffold implantation, an initial callus reac-
tion was seen around the implants during radiological
control X-rays. In all animals, the callus reaction
occurred at both the proximal and distal part of the
tibia.
Both the radiographs and the CT analyses at 3
months demonstrated new bone formation predomin-
ately at the posterior aspect of the tibia, opposite to the
site of surgery and close to the flexor muscles of the
lower leg (Figure 3(a) and (b)).
The PCL scaffold was still visible at 3 months after
implantation (Figure 3(c)) and completely intermingled
with connective tissue, firm connective tissue, cartilage,
and bone. New bone formation was mostly localized at
the peripheral zone of the scaffold stack. Small islets of
new bone matrix were present at the inner parts of the
scaffolds straight around the scaffold fibers. The new
bone matrix enclosed the scaffold fibers without any
fibrous interface (Figure 3(d) and (e)). No inflamma-
tory reaction was visible around the implant material
after 3 months. 1A4 Actin staining proved complete
vascularization of the scaffold (Figure 3(f)).
Quantification of the bone volume ratio at 3 months
Based on the CT quantification of newly produced
bone volume in the defect zone, new bone formation
in all four animals reached an average of 63% (þ/
37%). Two of four sheeps (Figure 5) showed almost
100% of new bone mass within the defect zone whereas
the other two animals revealed substantially less (28%
and 34%). CT quantification of a 3 cm midshaft bone
segment of the contralateral tibiae was used as refer-
ence value (100%).
Radiography and mCT at 12 months
The 12-month radiographs and mCT scans revealed that
two out of four tibial defects were bridged completely.
Most of the new bone was seen opposite to the site of
surgery. New bone formation occurred from both the
proximal and distal bone ends toward the defect.
One out of four animals showed a hypertrophic non-
union (Figure 4(b)) and one an atrophic nonunion
(Figure 4(d)). Both animals presenting a nonunion
after 12 months had to be stabilized with a cerclage
wire after nail insertion during surgery (see radiograph
in Figure 4(d)).
Quantification of the bone volume ratio at 12
months
Based on the mCT quantification of the 12-month
group, the newly formed bone averaged 172% (þ/
86%) as compared to the intact contralateral tibiae
used as a reference value (100%; Figure 5). The total
bone volume averaged 12,262mm3 (þ/6148mm3)
within the defect area compared to 7194mm3
(1008mm3) bone at the reference site. One animal
(number 3 in Figure 5) showed substantially less
658 Journal of Biomaterials Applications 28(5)
(43%) new bone compared with the other three of this
group (215% (þ/9%)).
Biomechanical estimation at 12 months
The average maximum load until failure of the non-
operated tibiae averaged 5875N (559N). Two oper-
ated tibiae reached 49% (2880N) and 63% (3720N) of
the reference value for normal bone, respectively
(Figure 6(a)). The values in the other two animals
were in a lower range of 18% (1050N) and 7% (428N).
The average stiffness of the contralateral tibiae aver-
aged 387N/mm (33N/mm; Figure 6). Two of four
animals reached a maximum stiffness of 46% (179N/
mm) and 40% (155N/mm) of the control value,
whereas, the other two animals reached only 20%
(82N/mm) and 4% (16N/mm) of the stiffness of the
contralateral tibiae (Figure 6(b)).
Physiological and histological evaluation
at 12 months
New bone formation was observed macroscopically in
all explants. After longitudinal sectioning of the tibiae,
the scaffold zone was still detectable (Figure 7(b)). The
implant was completely integrated into newly formed
bone. Most of the bone was seen at the posterior aspect
of the tibia, opposite to the site of surgery. The new
bone matrix enclosed the scaffold fibers without any
fibrous interface.
Histological staining revealed a new bone formation
at both the proximal and distal bone ends within and
outside the scaffold-stack. Fibrous tissue and cartilage
were seen as well (data not shown). The scaffold was
completely vascularized and erosion of the PCL-fibers
was clearly visible. No inflammatory reaction was evi-
dent around the implant material after 12 months.
Discussion
Previous studies using embroidered scaffolds in other
model systems demonstrated that they can act as a tem-
porary structure for cell migration, proliferation, and
differentiation in vitro and in vivo. The use of ECM
components like coll I/CS-enhanced osteogenic differ-
entiation and bone matrix accumulation.16,22,26 The
aim of this study was to evaluate the healing properties
of coll I/CS-coated PCL scaffolds in a large animal
Figure 3. Radiography, computer tomography and histology at 3 months. (a) to (d) presents the data of the animal with the highest
new bone formation in the 3 month group. The intramedullary nail and screws were removed after explantation. (a) x-ray of a sheep
tibia; (b) 3 dimensional CT reconstruction of a sheep tibia; (c) to (e) present images of modified Masson-Goldner Trichrome staining.
(c) histological cross section was taken of the central defect part, new bone formation occurred mainly at the outer scaffold part;
(d) histological cross section of the central defect part, inner scaffold area showed small islets of new bone formation; (e) The scaffold
was completely intermingled with vascularized, connective and firm connective tissue showing a new bone formation around scaffold
fibres; (f) 1 A4 Actin staining proved complete vascularization of the scaffold.
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pilot study. A critical size defect in the sheep tibia was
filled with a three-dimensional scaffold and investigated
after 3 and 12 months.
Surgical procedure
The two-step surgery according to Masquelet27 and
Viateau et al.9 seemed to be appropriate to form a
vascularized, fibrous tissue (‘periost-like membrane’)
surrounding the defect area after 6 weeks and repre-
sents a clinically relevant model. The mechanical stabil-
ization is achieved in a first step whereas the tissue
engineering is employed in a second step after eradica-
tion of an infection treatment or resection/irradiation
of a tumor. Because the periosteum was completely
removed within the defect region, the observed new
bone formation seems to have been generated in part
by the ‘periost-like membrane’.
The critical size defect of 3 cm and the intramedul-
lary nail fixation were selected based on literature
data.8,23,28–30 Although all animals had the same age
and weight, the tibia size differed and thus altered the
fitting of the single-sized intramedullary nail.
Additional fractures, treated with a cerclage, and prob-
ably unknown microfractures may be responsible for
the considerable variation of the presented results
including a hypertrophic and atrophic nonunion.
Concluding, the stability of the osteosynthesis in this
pilot study seems insufficient.
A total of 2 out of 10 animals displayed a broken
marrow nail at the 6 weeks X-ray control (after
implantation of the PCL scaffold) and were excluded
from the experiment. It is supposed that the hardware
failure occurred during uncontrolled full weight bearing
by the animals. Both, Reichert et al.31 and Hahn et al.32
described complications occurring during full weight
bearing involving peak loads during laying down and
standing up.31,32 However, all described mechanically
fixation systems in animal models, like intramedullary
nailing, external fixation, or plate fixation have poten-
tial disadvantages like thermal necrosis, reduced
intraosseous blood flow, infection or hardware loosen-
ing.31,32 Recently, a low contact dynamic compression
plate has been suggested for further experiments.32
Bone quantification
Bone quantification was performed using CT (3-month
group) and mCT (12-month group). The current pilot
study revealed a mean new bone formation of 63% and
172% after 3 and 12 months, respectively. To estimate
the value of new bone formation using coll I/CS coated
Figure 4. Radiography and CT at 12 months: (a) control tibia, (b) hypertrophic nonunion, (c) bridged defect, (d) atrophic nonunion,
and (e) bridged defect. The intramedullary nail and screws are visible in the radiographs of the operated tibiae (top row), for CT
analysis, the intramedullary nail and screws had been removed (bottom row).
CT: computer tomography.
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PCL scaffolds, these numbers were compared to that of
nine relevant large animal studies (Table 1).
All of these studies expressed the final amount of
newly formed bone as a percentage of normal bone
and therefore seemed to be appropriate for comparison.
In summary, the published reports indicate that
implants without cells formed approximately 17% of
new bone. Empty controls showed a mean bone
volume of 13% and controls with autologous bone
grafting, a mean bone volume of 46% (Table1). Most
large animal studies offer observation periods of 12 or
16 weeks and only two of them up to 6 months.
Compared to the available data from the literature,
this pilot study presents a higher amount of new bone
formation in the 3-month group than any other inves-
tigated scaffold in large animal experiments. With an
average amount of 63% of new bone after 3 months,
this study surpasses the values of that with autologous
bone grafting (46%) from the literature.
Mastrogiacomo et al.40 describe one of the rare long-
term studies for critical size bone defects in large ani-
mals. They investigated five sheep for 12 months using
resorbable bioceramics based on silicon-stabilized tri-
calcium phosphate. The authors achieved around
60% of new bone after 12 months analyzing microra-
diograph sections, which is considerably less than in
this study with two fully bridged defects showing
around 220% of new bone formation. This large
amount of bone originates from the strong callus for-
mation within the defect area. The lower bone forma-
tion in the study by Mastrogiacomo et al.40 could have
been due to the larger defect size of 4.8 cm. All com-
parisons have to be interpreted with caution
considering the different study designs and the small
number of animals in the present pilot study.
Biomechanics
The quantity of the newly formed bone is not the only
important factor in bone healing. The bone quality,
including cortical and trabecular structure, thickness
and porosity provide evidence for the apparent mech-
anical properties.41 The measured biomechanical stabil-
ity (load to failure) of 63% and 49% in the two bridged
defects compared to the non-operated tibia after 12
months are encouraging for planning further animal
studies using a greater number of animals. It is difficult
to interpret the obtained data because no relevant bio-
mechanical studies in large animals are available. They
may, however, serve as a reference for future
experiments.
Histological evaluation
A highly osteogenic activity was seen in connective
tissue–bone interfaces next to bone–cartilage interfaces
which points to endochondral and intramembraneous
ossification in healing of a critical size bone defect.
Endochondral ossification (soft callus remodeling) rep-
resents a typical fracture healing stage according to the
four-stage model.42 All histologically stained sections
present the third stage (hard callus formation) of the
fracture healing according to Schindler et al.42
The scaffold was completely intermingled with vas-
cularized connective tissue, showing bony islets around
the PCL fibers at the inner part of the scaffold after 3
250
225
200
175
150
125
100
75
50
25
B
o
n
e
 v
o
lu
m
e
 i
n
 %
0
34 96 28 95
1 2 3 4 5
224 205 43 215
100100
1 2 3 4 5
operated tibia
contralat. ref.
3 month group 12 month group
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months, and intermediate states of bone formation
within the scaffold after 12 months (Figures 3(f)
and 7(f)).
There was no inflammation or necrotic tissue detect-
able at both time points. The three-dimensional PCL
scaffold stack did not result in any tissue defects, cysts,
or non-vascularized areas after 3 or 12 months.
PCL scaffold
The coll I/CS PCL scaffold provides an appropriate
network of material with interconnecting pores to act
as a temporary matrix for new bone formation similar
to autologous bone. Reichert et al.32 specifies exactly
these conditions for implants used in long bone engin-
eering. Not fully interconnected and irregularly shaped
pores often lead to insufficient vascularization.43 If the
pores are too small, pore blocking by the cells will
happen and so inhibit cellular penetration of the inner
part of the scaffolds. The triaxial structure used in this
study resulted in an open porosity of 80% and in full
connective micro and macropores. This allows cell
penetration and proper vascularization of the scaffold.
The microporosity, resulting from the coll I/CS coating
(<100 mm), should improve bone ingrowth into the
scaffold by increasing the surface area for protein
adsorption44 and the vascularization.45
Poly("-caprolactone) alone has a very slow degrad-
ation rate up to 4 years, but the presence of poly(lactic
acid) will accelerate the degradation.17,46 The used PCL
fiber shows a degradation rate of around 25 weeks via
hydrolysis at in vitro as well as in vivo (rats, subcuta-
neous implantation) investigations.18 The PCL material
used in this study was still visible after 1 year of
implantation. This is not surprising, given that the
extent and the mechanism of the polymer hydrolysis
are depending on the amount, the presence, and the
location of water molecules.46 However, it is well
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Figure 6. Biomechanical evaluation at 12 months: (a) maximum load until failure in N and (b) stiffness in N/mm. The gray bars
represent the data of each animal. The black bar represents the average value of the contralateral tibiae as a reference.
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Figure 7. Histological evaluation: (a) representative picture of an explanted tibia after biomechanical testing, sectioned along the
longitudinal axis by sawing, (b) implanted PCL-scaffold is marked by the black line, (c) the histological section plane is comparable with
that of Figure 7(b), (d) higher magnification of Figure 7(c), the scaffold is completely intermingled with bone, (e) higher magnification of
Figure 7(d) shows vessel formation within the scaffold as well as lamellar bone structures with osteons, (f) higher magnification of
Figure 7(d) presenting lamellar bone structures with osteons and osteocytes and new formed blood vessels.
(c) to (f) represent Masson–Goldner trichrome staining.
PCL: polycaprolactone-co-lactide.
Table 1. Literature analysis.
Publication
Animal
number/group
Animal and
defect location
Defect
size (cm)
Time of
study (weeks) Implant
Bone
volume (%)
Anderson et al.33 12 animals with 24
defects, n¼ 6
Goat, iliac wing 1.7 12 Empty 13.5
Autologous bone 36.3
Allogenic bone 18.5
Copolymer 1.5
Arinzeh et al.
and Bruder et al.34,35
n¼ 6 Dog, femora 2.1 16 Empty <10
HA/bTCP 24.6
Bensaı̈d et al.7 n¼ 4 Sheep, metatarsus 2.5 16 Empty 8
n¼ 5 Autologous bone 30
n¼ 6 Coral 12
n¼ 7 CHA 13
(continued)
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accepted that a scaffold for bone reconstruction should
be able to provide mechanical support up to 1 year.
During this time, new bone tissue should be grown
and the mechanical support of the scaffold should
start to transfer back.46
Conclusion
This pilot study has demonstrated that embroidered
and biologically modified coll I/CS PCL scaffolds pro-
vide an appropriate network of pores to permit a com-
plete vascularization and bone tissue formation within
a critical size bone defect in a preclinical large animal
model. These preliminary data are encouraging for
future experiments with a larger group of animals and
different fixation methods.
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